Bioavailability of Maqui Berry Extract (MBE) in Healthy Subjects

Overview

The aim of the present study is to describe the bioavailability for the proprietary standardized maqui berry extracts Delphinol® and MaquiBright® enriched in anthocyanins and in particular delphinidins. The analyses are based on two selected key substances namely delphinidin-3-glucoside and cyanidin-3-sambubioside and their metabolism to phenolic acids. The bioavailability of anthocyanins specific for Delphinol®/MaquiBright® was analyzed in plasma sample kinetics (at 0h, 0.5h, 1h, 1.5h, 2h, 3h, 4h, 6h and 8h after intake of 1000mg standardized maqui berry extract in capsules) in 12 healthy subjects.

Full Title of Study: “Bioavailability of Maqui Berry Extracts (Delphinol® / MaquiBright®) in Healthy Subjects”

Study Type

• Study Type: Observational
• Study Design
  • Time Perspective: Prospective
• Study Primary Completion Date: December 12, 2017

Interventions

• Dietary Supplement: Standardized maqui berry extract enriched in anthocyanins
  • Single oral intake of 1000mg standardized maqui berry extract (in 4 capsules – 250mg each) with 200ml still water

Arms, Groups and Cohorts

• Maqui Berry Extract (MBE)
  • To be tested for the extracts bioavailability

Clinical Trial Outcome Measures

Primary Measures

• Quantification of two specific maqui berry anthocyanins: namely Delphinidin-3-O-glucoside and Cyanidin-3-O-sambubioside in a kinetics, evaluating the change between baseline and selected time points (see below).
  • Time Frame: Kinetics: baseline to 0.5 hours, 1 hour, 1.5 hours, 2 hours, 3 hours, 4 hours, 6 hours and 8 hours after intake
  • Specific anthocyanins related to maqui berry extract (Delphinol® / MaquiBright®) were measured in plasma samples of healthy subjects and assessed as change to baseline. Method: LC-MS/MS (unit [nmol/L]).
• Quantification of two specific maqui berry anthocyanin derived metabolites: namely gallic acid and protocatechuic acid in a kinetics, evaluating the change between baseline and selected time points (see below).
  • Time Frame: Kinetics: baseline to 0.5 hours, 1 hour, 1.5 hours, 2 hours, 3 hours, 4 hours, 6 hours and 8 hours after intake
  • Specific anthocyanin derived metabolites related to maqui berry extract (Delphinol® / MaquiBright®) were measured in plasma samples of healthy subjects and assessed as change to baseline. Method: LC-MS/MS. Results will most probably be assessed as “AUC” (area under the curve).
• Ferric reducing ability of plasma (FRAP) measurement in a kinetics, evaluating the change between baseline and selected time points (see below).
  • Time Frame: Kinetics: baseline to 0.5 hours, 1 hour, 1.5 hours, 2 hours, 3 hours, 4 hours, 6 hours and 8 hours after intake
  • The FRAP assay was performed to assess the “antioxidant power” / “antioxidant capacity” of the plasma after intake of maqui berry extract (Delphinol® / MaquiBright®). Method: photometric / absorption maximum at 593 nm (unit [µmol/l])

Participating in This Clinical Trial

Inclusion Criteria

1. Subject is able and willing to sign the Informed Consent Form prior to screening evaluations 2. Sex: female and male 3. Age: 18- 50 years 4. BMI ≥19 or ≤30 kg/m² 5. Non-smoker 6. Subject is in good physical and mental health as established by medical history, physical examination, electrocardiogram, vital signs, results of biochemistry, haematology Exclusion Criteria:

Subjects who met one or more of the following criteria are not eligible: 1. Relevant history or presence of any medical disorder, potentially interfering with this study (e.g. mal absorption, chronic gastro-intestinal diseases, etc.) 2. For this study clinically relevant abnormal laboratory, ECG, vital signs or physical findings at screening 3. Coffee consumption >3 cups / day 4. Consumption of more than 5 portions fruits and vegetables per day 5. Blood donation within 1 month prior to study start or during study 6. Regular intake of drugs or supplements possibly interfering with this study (e.g. Vitamin C, E, OPC etc.) within 2 weeks prior to study start or during study (Vitamin D with highest dosage of 1000 I.E. per day will be allowed) 7. Vegetarians / vegans 8. Drug-, alcohol- and medication abuses 9. Known HIV-infection 10. Known acute or chronic hepatitis B and C infection 11. Relevant allergy or known hypersensitivity against compounds of the study preparations 12. Known pregnancy, breast feeding or intention to become pregnant during the study 13. Participation in another clinical study within the last 4 weeks and concurrent participation in another clinical study 14. Anticipating any planned changes in lifestyle for the duration of the study

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 50 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

• Lead Sponsor
  • Anklam Extrakt
• Collaborator
  • BioTeSys GmbH
• Provider of Information About this Clinical Study
  • Sponsor